Results 151 to 160 of about 22,526 (252)

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

open access: yesMed Research, Volume 2, Issue 2, Page 309-342, June 2026.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Effect of Capsaicin (8%) Topical System on Sensory Function in Patients With Diabetic Peripheral Neuropathy: Analysis of the PACE Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1109-1117, June 2026.
This graphical abstract provides a summary of the analysis of the PACE study that evaluated the effect of high‐concentration capsaicin topical system (HCCTS) on sensory function in patients with DPN. From left to right: Progression of untreated DPN; Research question for current analysis; Outcomes used to evaluate sensory function; Intervention; Main ...
Nathaniel P. Katz   +4 more
wiley   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, Volume 45, Issue 5, Page 929-936, June 2026.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk   +7 more
wiley   +1 more source

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first‐in‐human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE). This was a single center, randomized, double‐blind, placebo controlled, single ascending dose (SAD) and FEstudy in healthy Chinese
Ying Yang   +14 more
wiley   +1 more source

The neuroimmune axis and chronic pain disorders. [PDF]

open access: yesiScience
Feenstra RA, den Dunnen WFA, Laman JD.
europepmc   +1 more source

A Combined Colon Organoid‐Sensory Neuron Model Reveals Epithelial Contribution to Moringin Efficacy Against Painful Inflammatory Bowel Disease

open access: yesPhytotherapy Research, Volume 40, Issue 6, Page 3250-3266, June 2026.
Experimental workflow and main findings of the study. ABSTRACT Visceral pain is a major symptom of inflammatory bowel diseases (IBDs), requiring effective treatment strategies. Gut epithelium, beyond maintaining barrier integrity and microbiota homeostasis, modulates neurosensorial circuitries, influencing visceral sensitivity.
Francesco Margiotta   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy